Onabotulinum toxin A for treatment of chronic migraine with medication overuse

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.

Original languageEnglish
JournalNeurological Sciences
Volume34
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2013

Fingerprint

Type A Botulinum Toxins
Migraine Disorders
Muscle Hypertonia
Clostridium botulinum
Headache Disorders
Anaerobic Bacteria
Neurotoxins
Analgesics
Therapeutics
Prescription Drug Overuse
onabotulinumtoxinA

Keywords

  • Chronic migraine
  • Medication overuse
  • Onabotulinum toxin A

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Cite this

Onabotulinum toxin A for treatment of chronic migraine with medication overuse. / Grazzi, L.

In: Neurological Sciences, Vol. 34, No. SUPPL. 1, 2013.

Research output: Contribution to journalArticle

@article{18a99ab6449a4eaa81cd808ed7065a03,
title = "Onabotulinum toxin A for treatment of chronic migraine with medication overuse",
abstract = "Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.",
keywords = "Chronic migraine, Medication overuse, Onabotulinum toxin A",
author = "L. Grazzi",
year = "2013",
doi = "10.1007/s10072-013-1381-1",
language = "English",
volume = "34",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Onabotulinum toxin A for treatment of chronic migraine with medication overuse

AU - Grazzi, L.

PY - 2013

Y1 - 2013

N2 - Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.

AB - Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.

KW - Chronic migraine

KW - Medication overuse

KW - Onabotulinum toxin A

UR - http://www.scopus.com/inward/record.url?scp=84892503773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892503773&partnerID=8YFLogxK

U2 - 10.1007/s10072-013-1381-1

DO - 10.1007/s10072-013-1381-1

M3 - Article

C2 - 23695040

AN - SCOPUS:84892503773

VL - 34

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 1

ER -